See up to 3 months of BRVE. The 7-day demo opens the 1M and 3M ranges and puts BRVE on your watchlist.
Start 7-day demoLatest BRVE insider trades
About Braveheart Bio, Inc. (BRVE)
Braveheart Bio, Inc. is an SEC registrant, filing under CIK 0002131524, classified as pharmaceutical preparations. It is grouped with Health Care companies on this site. Its offering priced on 6 August 2026 and it trades on NASDAQ.
BRVE Form 4 activity by transaction type, last 90 days
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market purchase | 13 | 8,835,275 | $159.03M |
| Grant or award | 9 | 1,360,000 | |
| Other acquisition / disposition | 12 | 279,440,638 |
BRVE insider transactions (Form 4)
3414 Form 4 filings on record, the earliest from Aug 7, 2026, newest first.
| Traded | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| AH Bio Fund IV, L.P. - 10% Owner | Other | Common Stock | 9,132,420 | - footnote F1 | - | |
| AH Bio Fund IV, L.P. - 10% Owner | Open-market purchase | Common Stock | 1,100,000 | $18.00 | $19.80M | |
| AH Bio Fund IV, L.P. - 10% Owner | Other | Series A Preferred Stock | 40,000,000 | $0.00 | - | |
| ||||||
| Erez Chimovits - Director | Other | Common Stock | 9,132,420 | - footnote F1 | - | |
| Erez Chimovits - Director | Open-market purchase | Common Stock | 1,666,667 footnote F2 | $18.00 | $30.00M | |
| Erez Chimovits - Director | Open-market purchase | Common Stock | 273,333 footnote F2 | $18.00 | $4.92M | |
| Erez Chimovits - Director | Other | Series A Preferred Stock | 40,000,000 | $0.00 | - | |
| ||||||
| ORBIMED ADVISORS LLC - Director | Other | Common Stock | 9,132,420 | - footnote F1 | - | |
| ORBIMED ADVISORS LLC - Director | Open-market purchase | Common Stock | 1,666,667 footnote F2 | $18.00 | $30.00M | |
| ORBIMED ADVISORS LLC - Director | Open-market purchase | Common Stock | 273,333 footnote F2 | $18.00 | $4.92M | |
| ORBIMED ADVISORS LLC - Director | Other | Series A Preferred Stock | 40,000,000 | $0.00 | - | |
| ||||||
| Jiangsu Hengrui Pharmaceuticals Co., Ltd. - 10% Owner | Other | Common Stock | 7,420,091 | - footnote F1 | - | |
| Jiangsu Hengrui Pharmaceuticals Co., Ltd. - 10% Owner | Other | Non-voting Series A preferred stock | 32,500,000 | $0.00 | - | |
| ||||||
| Forbion Growth Opportunities Fund III Cooperatief U.A. - 10% Owner | Other | Common Stock | 9,132,420 | $0.00 | - | |
| Forbion Growth Opportunities Fund III Cooperatief U.A. - 10% Owner | Other | Common Stock | 7,990,867 | $0.00 | - | |
| Forbion Growth Opportunities Fund III Cooperatief U.A. - 10% Owner | Open-market purchase | Common Stock | 1,920,000 | $18.00 | $34.56M | |
| Forbion Growth Opportunities Fund III Cooperatief U.A. - 10% Owner | Open-market purchase | Common Stock | 1,680,000 | $18.00 | $30.24M | |
| Forbion Growth Opportunities Fund III Cooperatief U.A. - 10% Owner | Other | Series A Preferred Stock | 40,000,000 | $0.00 | - | |
| Forbion Growth Opportunities Fund III Cooperatief U.A. - 10% Owner | Other | Series A Preferred Stock | 35,000,000 | $0.00 | - | |
| James Paul Rickey - Officer | Open-market purchase | Common Stock | 27,777 | $18.00 | $500K | |
| James Paul Rickey - Officer | Grant or award | Stock Option (Right to Buy) | 300,000 | $0.00 | - | |
| Tim Lohoff - Director | Grant or award | Stock Option (Right to Buy) | 30,000 | $0.00 | - | |
| Erez Chimovits - Director | Grant or award | Stock Option (Right to Buy) | 30,000 | $0.00 | - | |
| Christopher Viehbacher - Director | Open-market purchase | Common Stock | 83,333 | $18.00 | $1.50M | |
| Christopher Viehbacher - Director | Grant or award | Stock Option (Right to Buy) | 30,000 | $0.00 | - | |
| David I. Malek - Director | Open-market purchase | Common Stock | 4,166 | $18.00 | $75K | |
| David I. Malek - Director | Grant or award | Stock Option (Right to Buy) | 30,000 | $0.00 | - | |
| Michele A. Anderson - Officer | Open-market purchase | Common Stock | 1,111 | $18.00 | $20K | |
| Michele A. Anderson - Officer | Grant or award | Stock Option (Right to Buy) | 300,000 | $0.00 | - | |
| Travis Murdoch - Officer | Open-market purchase | Common Stock | 83,333 | $18.00 | $1.50M | |
| Travis Murdoch - Officer | Grant or award | Stock Option (Right to Buy) | 550,000 | $0.00 | - | |
| Jasper Bos - Director | Grant or award | Stock Option (Right to Buy) | 30,000 | $0.00 | - | |
| David Charles Lubner - Director | Open-market purchase | Common Stock | 55,555 | $18.00 | $1.00M | |
| David Charles Lubner - Director | Grant or award | Stock Option (Right to Buy) | 60,000 | $0.00 | - | |
Item 2.02, 9.01
Item 5.03, 9.01
BRVE insider trading FAQ
What is the latest insider trade for BRVE?
Braveheart Bio, Inc. (BRVE) had 14 insider filings in the last 90 days, with the most recent on 11 August 2026. The full record for BRVE runs to 14 Form 4 filings, the earliest from 7 August 2026. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying BRVE stock?
13 insider purchases of BRVE were filed in the last 90 days, totaling $159.03M.
How many insiders are selling BRVE stock?
No insider sales of BRVE were filed in the last 90 days.
Where can I see BRVE SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects BRVE Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - AH Bio Fund IV, L.P. view on EDGAR
- - Erez Chimovits view on EDGAR
- - ORBIMED ADVISORS LLC view on EDGAR
- - Jiangsu Hengrui Pharmaceuticals Co., Ltd. view on EDGAR
- - Forbion Growth Opportunities Fund III Cooperatief U.A. view on EDGAR
- - James Paul Rickey view on EDGAR
- - Tim Lohoff view on EDGAR
- - Erez Chimovits view on EDGAR
- - Christopher Viehbacher view on EDGAR
Related companies with recent insider activity
Learn more
- How to read insider buying signals
- What an open-market purchase by an insider can and cannot tell you.
- Insider activity in Health Care
- Where BRVE's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow BRVE with a 7-day demo
- BRVE on your watchlist
- Every BRVE Form 4 filing on record
- Up to 3 months of BRVE price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
Start 7-day demoCard required. Your card is never charged for the demo.
